Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$12.78 |
52 Week High | HK$13.04 |
52 Week Low | HK$6.02 |
Beta | 0.19 |
1 Month Change | 21.48% |
3 Month Change | 37.12% |
1 Year Change | 71.54% |
3 Year Change | 44.41% |
5 Year Change | -34.96% |
Change since IPO | 75.79% |
Recent News & Updates
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce
Mar 01Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%
Mar 01YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't
Jan 03Recent updates
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) P/S Is Still On The Mark Following 33% Share Price Bounce
Mar 01Investors Appear Satisfied With YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Prospects As Shares Rocket 33%
Mar 01YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Business Is Trailing The Industry But Its Shares Aren't
Jan 03YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Could Easily Take On More Debt
Sep 25Does YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Have A Healthy Balance Sheet?
Nov 25Is YiChang HEC ChangJiang Pharmaceutical (HKG:1558) A Risky Investment?
Mar 23Does This Valuation Of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Imply Investors Are Overpaying?
Oct 29Here's Why YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Has A Meaningful Debt Burden
Apr 13YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Analysts Just Cut Their EPS Forecasts Substantially
Mar 23YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Share Price Is Down 55% Over The Past Three Years.
Mar 13YiChang HEC ChangJiang Pharmaceutical (HKG:1558) Is Growing Earnings But Are They A Good Guide?
Feb 20Do Institutions Own YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (HKG:1558) Shares?
Feb 02YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Dec 26Key Things To Watch Out For If You Are After YiChang HEC ChangJiang Pharmaceutical Co., Ltd.'s (HKG:1558) 5.1% Dividend
Dec 13What Type Of Returns Would YiChang HEC ChangJiang Pharmaceutical's(HKG:1558) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Nov 30Shareholder Returns
1558 | HK Pharmaceuticals | HK Market | |
---|---|---|---|
7D | 1.9% | -4.1% | -2.8% |
1Y | 71.5% | -21.9% | -15.0% |
Return vs Industry: 1558 exceeded the Hong Kong Pharmaceuticals industry which returned -22.4% over the past year.
Return vs Market: 1558 exceeded the Hong Kong Market which returned -16.4% over the past year.
Price Volatility
1558 volatility | |
---|---|
1558 Average Weekly Movement | 8.7% |
Pharmaceuticals Industry Average Movement | 6.2% |
Market Average Movement | 7.4% |
10% most volatile stocks in HK Market | 14.8% |
10% least volatile stocks in HK Market | 3.8% |
Stable Share Price: 1558's share price has been volatile over the past 3 months.
Volatility Over Time: 1558's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2001 | 4,618 | Juncai Jiang | cj.hec.cn |
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases, cardiovascular diseases, and anti-infection diseases in the People’s Republic of China. It manufactures and sells active pharmaceutical ingredients; researches and develops pharmaceutical products, and medical devices and drugs, as well as biotechnology; and provides medical consulting services.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Fundamentals Summary
1558 fundamental statistics | |
---|---|
Market cap | HK$11.25b |
Earnings (TTM) | HK$2.16b |
Revenue (TTM) | HK$6.81b |
5.2x
P/E Ratio1.7x
P/S RatioIs 1558 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1558 income statement (TTM) | |
---|---|
Revenue | CN¥6.29b |
Cost of Revenue | CN¥1.31b |
Gross Profit | CN¥4.99b |
Other Expenses | CN¥2.99b |
Earnings | CN¥1.99b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 2.26 |
Gross Margin | 79.21% |
Net Profit Margin | 31.66% |
Debt/Equity Ratio | 32.9% |
How did 1558 perform over the long term?
See historical performance and comparison